Starpax Biopharma
Starpax Biopharma is a dual Biopharma/Medtech company pioneering a revolutionary platform for cancer treatment. Their core technology involves Starpax Magnetodrones™, which are self-propelled, magnetotactic bacteria carrying therapeutic agents. These Magnetodrones are injected directly into tumors and guided by the Starpax PolarTrak™, a proprietary medical device that uses magnetic fields and AI to ensure precise 3D distribution within the tumor, including hard-to-reach hypoxic zones. This approach aims to deliver a higher concentration of drugs directly to the tumor, avoid circulating in the bloodstream, and minimize side effects compared to traditional chemotherapy, radiation, immunotherapy, and surgery. The company has developed a GMP manufacturing plant in Canada for its Magnetodrones and is planning clinical trials to commence in 2025 for various cancer indications, as well as non-cancerous diseases like ischemic heart disease and pulmonary hypertension. The technology is investigational and not yet approved for commercial use.
Starpax Biopharma
Starpax Biopharma is a dual Biopharma/Medtech company pioneering a revolutionary platform for cancer treatment. Their core technology involves Starpax Magnetodrones™, which are self-propelled, magnetotactic bacteria carrying therapeutic agents. These Magnetodrones are injected directly into tumors and guided by the Starpax PolarTrak™, a proprietary medical device that uses magnetic fields and AI to ensure precise 3D distribution within the tumor, including hard-to-reach hypoxic zones. This approach aims to deliver a higher concentration of drugs directly to the tumor, avoid circulating in the bloodstream, and minimize side effects compared to traditional chemotherapy, radiation, immunotherapy, and surgery. The company has developed a GMP manufacturing plant in Canada for its Magnetodrones and is planning clinical trials to commence in 2025 for various cancer indications, as well as non-cancerous diseases like ischemic heart disease and pulmonary hypertension. The technology is investigational and not yet approved for commercial use.